Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
Res Pract Thromb Haemost. 2022 Sep 20;6(6):e12795. doi: 10.1002/rth2.12795. eCollection 2022 Aug.ABSTRACTIntravenous thrombolysis is a standard of care treatment for patients with acute ischemic stroke. Tissue plasminogen activator (tPA) has been the main thrombolytic agent used since the publication of the seminal National Institutes of Neurological Disorders and Stroke trial in 1995. There is now mounting evidence to support the routine use of Tenecteplase (TNK) to treat acute ischemic stroke. TNK is a genetically modified tPA with higher fibrin specificity, longer half-life, and reduced systemic coagulopathy. In this il...
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Annie Zhu Phavalan Rajendram Eric Tseng Shelagh B Coutts Amy Y X Yu Source Type: research

Desmopressin testing in von Willebrand disease: Lowering the burden
CONCLUSION: Desmopressin testing is not needed when lowest historical VWF:Act is 0.30 IU/ml or greater. In patients with Type 1 VWD who require testing, measurements after T1 are often not needed. In patients with Type 2 VWD who require testing, we advise performing T1 and T4 measurements.PMID:36186107 | PMC:PMC9512764 | DOI:10.1002/rth2.12784 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Jessica M Heijdra Ferdows Atiq Wala Al Arashi Quincy Kieboom Esmee Wuijster Karina Meijer Marieke J H A Kruip Frank W G Leebeek Marjon H Cnossen OPTI ‐CLOT Study Group Source Type: research

Acquired hemophilia following COVID-19 vaccination: Case report and review of literature
CONCLUSIONS: The diagnosis of AHA with a relapse of bullous pemphigoid was made. The patient was treated with recombinant activated factor VII, emicizumab, rituximab, and methylprednisolone. There were no further bleeding events. However, the patient deteriorated because of sepsis and died on the fifteenth day of admission.CONCLUSION: Vaccines may trigger autoimmune events such as AHA. However, proof of causality is not possible and in this case the relapse of bullous pemphigoid before vaccination challenges this even more.PMID:36176309 | PMC:PMC9459413 | DOI:10.1002/rth2.12785 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Michiel Happaerts Thomas Vanassche Source Type: research

Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States
CONCLUSIONS: Despite treatment with TPE and immunosuppressants, patients with iTTP have high risk of morbidity and mortality, demonstrating the need for more effective therapies.PMID:36176310 | PMC:PMC9481884 | DOI:10.1002/rth2.12802 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Ayoade Adeyemi Francesca Razakariasa Alexandra Chiorean Rui de Passos Sousa Source Type: research

Lupus anticoagulant associates with thrombosis in patients with COVID-19 admitted to intensive care units: A retrospective cohort study
CONCLUSION: Lupus anticoagulant on admission is strongly associated with thrombosis in critically ill patients with COVID-19, especially in patients aged less than 65 years.PMID:36178455 | PMC:PMC9481876 | DOI:10.1002/rth2.12809 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Tessa Noordermeer Roger E G Schutgens Chantal Visser Emma Rademaker Moniek P M de Maat A J Gerard Jansen Maarten Limper Olaf L Cremer Marieke J H A Kruip Henrik Endeman Coen Maas Bas de Laat Rolf T Urbanus Dutch COVID & Thrombosis Coalition (DCTC) Source Type: research

Impact of Asymptomatic Superior Mesenteric Vein Thrombosis on the Outcomes of Patients with Liver Cirrhosis
CONCLUSIONS: Asymptomatic SMV thrombosis may not influence the outcomes of cirrhotic patients. The timing of intervention for asymptomatic SMV thrombosis in liver cirrhosis should be further explored.PMID:36179738 | DOI:10.1055/s-0042-1756648 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Le Wang Xiaozhong Guo Zhaohui Bai Yue Yin Shixue Xu Jiahui Pan Andrea Mancuso Carlos Noronha Ferreira Xingshun Qi Source Type: research

Acquired hemophilia following COVID-19 vaccination: Case report and review of literature
CONCLUSIONS: The diagnosis of AHA with a relapse of bullous pemphigoid was made. The patient was treated with recombinant activated factor VII, emicizumab, rituximab, and methylprednisolone. There were no further bleeding events. However, the patient deteriorated because of sepsis and died on the fifteenth day of admission.CONCLUSION: Vaccines may trigger autoimmune events such as AHA. However, proof of causality is not possible and in this case the relapse of bullous pemphigoid before vaccination challenges this even more.PMID:36176309 | PMC:PMC9459413 | DOI:10.1002/rth2.12785 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Michiel Happaerts Thomas Vanassche Source Type: research

Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States
CONCLUSIONS: Despite treatment with TPE and immunosuppressants, patients with iTTP have high risk of morbidity and mortality, demonstrating the need for more effective therapies.PMID:36176310 | PMC:PMC9481884 | DOI:10.1002/rth2.12802 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Ayoade Adeyemi Francesca Razakariasa Alexandra Chiorean Rui de Passos Sousa Source Type: research

Lupus anticoagulant associates with thrombosis in patients with COVID-19 admitted to intensive care units: A retrospective cohort study
CONCLUSION: Lupus anticoagulant on admission is strongly associated with thrombosis in critically ill patients with COVID-19, especially in patients aged less than 65 years.PMID:36178455 | PMC:PMC9481876 | DOI:10.1002/rth2.12809 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Tessa Noordermeer Roger E G Schutgens Chantal Visser Emma Rademaker Moniek P M de Maat A J Gerard Jansen Maarten Limper Olaf L Cremer Marieke J H A Kruip Henrik Endeman Coen Maas Bas de Laat Rolf T Urbanus Dutch COVID & Thrombosis Coalition (DCTC) Source Type: research

Impact of Asymptomatic Superior Mesenteric Vein Thrombosis on the Outcomes of Patients with Liver Cirrhosis
CONCLUSIONS: Asymptomatic SMV thrombosis may not influence the outcomes of cirrhotic patients. The timing of intervention for asymptomatic SMV thrombosis in liver cirrhosis should be further explored.PMID:36179738 | DOI:10.1055/s-0042-1756648 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Le Wang Xiaozhong Guo Zhaohui Bai Yue Yin Shixue Xu Jiahui Pan Andrea Mancuso Carlos Noronha Ferreira Xingshun Qi Source Type: research

Acquired hemophilia following COVID-19 vaccination: Case report and review of literature
CONCLUSIONS: The diagnosis of AHA with a relapse of bullous pemphigoid was made. The patient was treated with recombinant activated factor VII, emicizumab, rituximab, and methylprednisolone. There were no further bleeding events. However, the patient deteriorated because of sepsis and died on the fifteenth day of admission.CONCLUSION: Vaccines may trigger autoimmune events such as AHA. However, proof of causality is not possible and in this case the relapse of bullous pemphigoid before vaccination challenges this even more.PMID:36176309 | PMC:PMC9459413 | DOI:10.1002/rth2.12785 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Michiel Happaerts Thomas Vanassche Source Type: research

Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States
CONCLUSIONS: Despite treatment with TPE and immunosuppressants, patients with iTTP have high risk of morbidity and mortality, demonstrating the need for more effective therapies.PMID:36176310 | PMC:PMC9481884 | DOI:10.1002/rth2.12802 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Ayoade Adeyemi Francesca Razakariasa Alexandra Chiorean Rui de Passos Sousa Source Type: research

Lupus anticoagulant associates with thrombosis in patients with COVID-19 admitted to intensive care units: A retrospective cohort study
CONCLUSION: Lupus anticoagulant on admission is strongly associated with thrombosis in critically ill patients with COVID-19, especially in patients aged less than 65 years.PMID:36178455 | PMC:PMC9481876 | DOI:10.1002/rth2.12809 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Tessa Noordermeer Roger E G Schutgens Chantal Visser Emma Rademaker Moniek P M de Maat A J Gerard Jansen Maarten Limper Olaf L Cremer Marieke J H A Kruip Henrik Endeman Coen Maas Bas de Laat Rolf T Urbanus Dutch COVID & Thrombosis Coalition (DCTC) Source Type: research

Impact of Asymptomatic Superior Mesenteric Vein Thrombosis on the Outcomes of Patients with Liver Cirrhosis
CONCLUSIONS: Asymptomatic SMV thrombosis may not influence the outcomes of cirrhotic patients. The timing of intervention for asymptomatic SMV thrombosis in liver cirrhosis should be further explored.PMID:36179738 | DOI:10.1055/s-0042-1756648 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Le Wang Xiaozhong Guo Zhaohui Bai Yue Yin Shixue Xu Jiahui Pan Andrea Mancuso Carlos Noronha Ferreira Xingshun Qi Source Type: research

Acquired hemophilia following COVID-19 vaccination: Case report and review of literature
CONCLUSIONS: The diagnosis of AHA with a relapse of bullous pemphigoid was made. The patient was treated with recombinant activated factor VII, emicizumab, rituximab, and methylprednisolone. There were no further bleeding events. However, the patient deteriorated because of sepsis and died on the fifteenth day of admission.CONCLUSION: Vaccines may trigger autoimmune events such as AHA. However, proof of causality is not possible and in this case the relapse of bullous pemphigoid before vaccination challenges this even more.PMID:36176309 | PMC:PMC9459413 | DOI:10.1002/rth2.12785 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - September 30, 2022 Category: Hematology Authors: Michiel Happaerts Thomas Vanassche Source Type: research